Investigating the sequential patterns of methamphetamine use initiation in Iran

Ebrahim Moghimi Sarani¹, Jamshid Ahmadi², Bahare Oji³, Motahareh Mahi-Birjand⁴,⁵, Nader Bagheri⁶, Amir Bazrafshan⁷, Marie Dehghan Manshadi⁸, Sajad Yaghoubi⁹, Asiyeh Dezhkam⁹, Mehrdad Khatami¹⁰ and Meghdad Abdollahpour-Alitappeh¹¹*

Abstract

Background: Methamphetamine (MA) remains one of the most commonly used amphetamine-type stimulants, accounting for the second most widely-used substance after marijuana. Due to increased use of MA, a wide variety of research has focused on the patterns of MA use initiation among adolescents. Nevertheless, there are few data available for people who use MA. The present study set out to assess the sequential patterns of substance use initiation in patients with MA use disorders in Iran.

Materials and methods: This cross-sectional study described substance initiation patterns for 302 patients who used MA admitted to hospitals and psychiatric centers of Shiraz University of Medical Sciences. The study was conducted between April 2015 and June 2016. After obtaining informed consents, participants were interviewed by trained interviewers using face-to-face, semi-structured interviews. The collecting data were analyzed using the chi square tests and one-way analysis of variance (ANOVA) tests to compare the relationship between qualitative and quantitative variables, respectively.

Results: Out of 302 participants enrolled in the study, 16 (5.3%) and 286 (94.7%) were female and male, respectively. The mean age of participants in the study was 37.29 years. The mean age of onset of MA use was found to be 15.9 years. 46.1% of the patients started MA use before 15 years. 77.2% of the patients who used MA had family members with a history of substance use. 93.71% of the patients who used MA started substance use with tobacco, alcohol, or opium, as the most frequent substances. Tobacco, as the first substance or starting substance, exhibited the most widely-used substance (69.53% of the cases). Tobacco-alcohol-cannabis-opium-heroin-MA sequencing was significantly related to the early onset of the substance use. Early-onset substance use was significantly higher in those with lower income, primary education, and family history of substance use. No significant relationship was found between employment status with the age of onset of substance use, and different substance use with marital status.

(Continued on next page)
Introduction
Amphetamines, as sympathomimetics and psychostimulants, are the most commonly-used drugs after cannabis in the UK, Australia, and several Western European countries. Methamphetamine (MA), a potent form of amphetamine first made in 1893 by Japanese researcher Nagai Nagayoshi 6 years after the discovery of amphetamine, has been one of the most commonly used substances in the world, so that the rate of substance use has tripled in the world, that is, the rate of substance use as compared with many countries in recent years as compared with the rate of population growth [9–13]. Although opium and cannabis are considered as traditional drugs of abuse in Iran, the use of heroin, crystal, ecstasy, and MA has increased in recent years [14]. In 2010, the Persian police reported a 50% decrease and 54% increase in seizing opiates and MA, respectively, as compared with 2009 [15]. It is estimated that there are 1.2–2 million users who are dependent on illicit drugs mainly opiates and MA. Epidemiological studies revealed the prevalence of MA use in 7, 73.9 and 13.3% of the adults in the general population of Tehran [16], truck drivers across the country [17] and male bodybuilders in Tehran [18], respectively. Increased physical energy, wakefulness, pleasure-seeking and professional performance were found to be the main reasons for MA use [15]. Analyses of substance use initiation and sequencing patterns may help find risk factors for other behaviors.

Considering the increased prevalence of the stimulant use such as MA in Iran, there is an urgent need to study the sequence and profile of substance use before MA use in Iran. Therefore, the present study was tailored to evaluate the sequential patterns of substance use initiation in patients with MA use disorders in Iran.

Materials and methods
Ethics statement
This study was carried out in accordance with the recommendations of ethical guidelines, IR.SUMS.REC.1394.S1206. The research protocol was approved by Shiraz University of Medical Sciences. All subjects were given written informed consent in accordance with the Declaration of Helsinki.

Design
This cross-sectional study was conducted between April 2015 and June 2016 to investigate the substance use in the patients who used MA and to find the sequential patterns of MA use. Our sample consisted of all patients who used MA admitted to hospitals and psychiatric hospitals affiliated to Shiraz University of Medical Sciences, including Ibn-e-Sina Psychiatric Educational Hospital, Hafez Educational Hospital, and Recovery Center during the study period.
Participants
In the centers that the samples were collected, all the people used substances and almost all the patients used MA. Interviews were conducted by a psychologist or assistant psychologist. The participants were evaluated at one-time point by face-to-face, semi-structured interviews for approximately 20–30 min. Those patients who met DSM5 diagnostic criteria for MA use disorders were included in the study. Only a small number of the patients who did not meet these criteria were excluded from the study (such as those who did not sign the consent form or lacked a good memory). In total, 302 patients (95% confidence coefficient and 5% error and alpha = 0.05) were participated in this study. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [19] to strengthen the methodology and report of the findings.

Inclusion criteria
Potential participants were eligible for the study if they met the following inclusion criteria:

- Age between 18 and 65 years old
- MA use over the past year based on DSM5 criteria
- DSM5 criteria for MA use disorders

Exclusion criteria
Patients were excluded from the study if they met one of the following exclusion criteria:

- People with cognitive impairment, severe aggression, and psychosis who were unable to cooperate in the interview and whose information was not sufficiently reliable at the time of the interview
- Discontent to participate in the study

Procedure
After obtaining written informed consent, qualified patients were interviewed and the required information was collected on the basis of a pre-prepared checklist. In-person interview checklist included:

- Demographic information including age, sex, marital status, occupation, income, and education
- The history of different types of substance use in the past year
- The age of the first substance use
- The first substance used
- Sequential use of substances from beginning up to now (to find sequential patterns)
- The history of substance uses in the family, the number of family members with substance use, and the type of substances used
- Previous history of admission to Psychiatric Hospital

Substances used were classified according to substance use and drug classification as follows:

- The tobacco group: including hookah and cigarettes
- The alcohol group: only including alcohol
- The cannabis group: including marijuana and cannabis
- The opium group: including opium and opium sap
- The heroin group: including heroin and crack
- The cocaine group: only including cocaine
- The Ritalin group: only including Ritalin
- The MA group: only including MA

Sequential profiling
The sequential patterns for MA use were determined based on the order of substance use in patients who used MA. In the questionnaire, we asked participants specifically about the order of the substances that they used before MA use.

Statistical analysis
The data were evaluated by SPSS software version 20. The results were analyzed by descriptive statistics, including mean ± standard deviation for quantitative variables and frequency tables for qualitative variables. In addition, chi-square and one-way analysis of variance (ANOVA) tests were used to compare the relationship between qualitative and quantitative variables, respectively. If the result of the ANOVA test was significant, a least significant difference test was applied to locate which of the means differed. P values < 0.05 were considered to be statistically significant.

Results
A total of 302 participants were enrolled in the study. Table 1 indicates demographic characteristics of the sample, including gender, age, education, monthly income, age of onset of substance use, history of hospitalization, the rate of substance use in the family, type of substances used in the family member, and type of substances used in the last year. The mean age of participants in the study was 37.29 years and the mean age of onset of substance use was found to be 15.9 years.

Based on the demographic characteristics, participants were divided into several groups, including the education level (including three groups, elementary education including illiterate and elementary education, secondary education/high school, and higher educational level including diploma and higher education); the monthly income (including three groups, low-income, middle-income, and high-income); the age of onset of substance use (including two groups, early and late onset); the
Table 1 Demographic characteristics of the study population

| Characteristics                          | Number (n = 302) | Percent |
|-----------------------------------------|------------------|---------|
| **Gender**                              |                  |         |
| Male                                    | 286              | 94.7%   |
| Female                                  | 16               | 5.3%    |
| **Age (years)**                         |                  |         |
| 18–40                                   | 187              | 61.7%   |
| Over 40                                 | 115              | 38.3%   |
| **Marital status**                      |                  |         |
| Single                                  | 95               | 31.5%   |
| Married                                 | 140              | 46.3%   |
| Divorced                                | 60               | 19.9%   |
| Widow                                   | 7                | 2.3%    |
| **Employment**                          |                  |         |
| Unemployed                              | 75               | 24.8%   |
| Employed                                | 227              | 75.2%   |
| Self-employed                           | 183              | 60.6%   |
| Employee                                | 37               | 12.2%   |
| Retired                                 | 5                | 1.7%    |
| Student                                 | 2                | 0.7%    |
| **Education**                           |                  |         |
| Elementary education                    | 55               | 18.2%   |
| Secondary education                     | 217              | 71.9%   |
| Higher education                        | 30               | 9.5%    |
| **Monthly income (Tomans)**             |                  |         |
| Low (< 500,000)                         | 148              | 49%     |
| Middle (500,000-2,000,000)              | 130              | 43.1%   |
| High (> 2,000,000)                      | 24               | 7.9%    |
| **Age of onset (years) of substance use**|                  |         |
| Early (< 15)                            | 139              | 46%     |
| Late (> 15)                             | 163              | 54%     |
| **History of hospitalization**          |                  |         |
| No                                      | 185              | 61.3%   |
| Yes; previous psychiatric hospitalization| 117              | 38.7%   |
| **Substance use in the family**         |                  |         |
| No                                      | 69               | 22.8%   |
| Yes                                     | 233              | 77.2%   |
| One member                              | 98               | 32.4%   |
| Two members                             | 59               | 19.5%   |
| Three members                           | 34               | 11.3%   |
| Four members                            | 18               | 6%      |
| Five members                            | 12               | 4%      |
| Six members                             | 5                | 1.7%    |
| Seven members                           | 7                | 2.3%    |
| **Type of substance use in the family members** |            |         |
| Stimulant substances                     | 47               | 15.6%   |
| Non-stimulant substances                 | 255              | 84.4%   |
| **Type of substance use in the last year** |              |         |
| Tobacco group                           | 290              | 96%     |
| Heroin group                            | 216              | 71.5%   |
| Opium group                             | 150              | 49.7%   |
| Cannabis group                          | 119              | 39.4%   |
| Alcohol group                           | 97               | 32.1%   |
| Cocaine group                           | 16               | 5.3%    |
| Ritalin group                           | 3                | 1%      |

*aElementary education including illiterate and elementary education; Secondary education including high school education; and Higher education including diploma and higher education

*bStimulant substances including Ritalin, amphetamines and cocaine

*cThe tobacco group, including hookah and cigarettes; the heroin group, including heroin and crack; the opium group, including opium and opium sap; the cannabis group, including marijuana and cannabis; the alcohol group, only including alcohol; the cocaine group, only including cocaine; and the Ritalin group, only including Ritalin (methylphenidate)
substance use in the family (including two groups, those with family members who used substances and did not use substances); type of substances used in the family members (including two groups, the family members who used stimulant substances including Ritalin, amphetamines and cocaine, and the family members who used non-stimulant substances); the substance type in the last year (the tobacco group including hookah and cigarette, heroin group including heroin and crack, opium group including opium and sap, cannabis group including marijuana and cannabis, alcohol group only including alcohol, cocaine group only including cocaine, and Ritalin group only including Ritalin (methylphenidate)).

As shown in Fig. 1, tobacco, as the first substance or starting substance, exhibited the most widely-used substance (69.5% of the cases), showing statistically significant differences ($p \leq 0.0001$). After tobacco, 13.6 and 10.6% of the patients who used MA started substance use with alcohol and opium, respectively, showing statistically significant differences ($p \leq 0.0001$). Other substances used included cannabis (3.3%), heroin (1.7%), and MA (1%), respectively. Only one case (0.3%) mentioned Ritalin as the first substance and no one (0%) started substance use with cocaine; in total, 93.71% of the patients who used MA started substance use with tobacco, alcohol, or opium.

The comparison between heroin and MA use showed that 41 of the patients who used MA started with MA earlier than heroin (13.58% of all the patients who used MA and 17.7% of the patients who used both heroin and MA). In contrast, 190 of the patients who used MA started with heroin earlier than MA (62.91% of all the patients who used MA and 82% of the patients who used both heroin and MA).

The comparison between cannabis and opium use demonstrated that 92 of the patients who used MA started with cannabis earlier than opium (30.46% of all the patients who used MA and 56.72% of the patients who used both cannabis and opium). In contrast, 70 of the patients who used MA started with opium earlier than cannabis (23.18% of all the patients who used MA and 43.2% of the patients who used both cannabis and opium).

The comparison between cannabis and tobacco use revealed that 167 of the patients who used MA started with tobacco earlier than cannabis (55.30% of all the patients who used MA and 93.29% of the patients who used both cannabis and tobacco). In contrast, 12 of the patients who used MA started with cannabis earlier than tobacco (3.97% of all the patients who used MA and 6.07% of the patients who used both cannabis and tobacco).

The comparison between alcohol and tobacco use indicated that 154 of the patients who used MA started with tobacco earlier than alcohol (50.99% of all the patients who used MA and 80.2% of the patients who used both alcohol and tobacco). In contrast, 38 of the patients who used MA started with alcohol earlier than tobacco (12.58% of all the patients who used MA and 19.79% of the patients who used both alcohol and tobacco).

The comparison between alcohol and opium use showed that 136 of the patients who used MA started with alcohol earlier than opium (45.03% of all the patients who used MA and 73.91% of the patients who used both alcohol and opium). In contrast, 48 of the patients who used MA started with opium earlier than alcohol (15.89% of all the patients who used MA and 26.08% of the patients who used both alcohol and opium).
The comparison between alcohol and cannabis use showed that 100 of the patients who used MA started with alcohol earlier than cannabis (33.11% of all the patients who used MA and 72.99% of the patients who used both alcohol and cannabis). In contrast, 37 of the patients who used MA started with cannabis earlier than alcohol (12.25% of all the patients who used MA and 27% of patients who used both alcohol and cannabis).

A variety of sequencing patterns was obtained in this study, the most common of which included:
- Sequencing D: tobacco-opium-hero-(n = 24).
- Sequencing F: cannabis-opium-MA (n = 20).
- Sequencing C: tobacco-opium-MA (n = 19).
- Sequencing E: cannabis-opium-MA (n = 17).
- Sequencing A: MA (n = 3).
- Sequencing B: tobacco-MA (n = 2).

Based on the age of onset of substance use, as mentioned above, patients were divided into two groups, including early onset and late onset; the comparison between sequencing patterns and the age of onset of substance use showed that sequencing F was significantly lower than sequencings C, D, and E (Table 2).

The comparison between the age of onset of substance use and current monthly income showed the number of patients who used MA with early onset of substance use was significantly higher in the low-income group (P-value = 0.006) (Table 3).

The comparison between the age of onset of substance use and education level showed that the number of patients who used MA with high education was lower in the early-onset group, while the number of patients who used MA with primary education was higher in the early-onset group. These findings were statistically significant (P-value = 0.04).

The comparison between the age of onset of substance use and the starting substance type showed no significant relationship. Table 4 indicates the mean age of patients who used MA in starting groups with different substances. The highest and lowest mean age was associated with MA (30 years) and cannabis (15.25 years) starting groups, respectively.

The comparison between substance use in the family and different sequences of substance use showed a higher rate of odds ratio (OR) for sequencing C, as a result of which early onset of substance use was correlated with family member uses. In other words, patients who used MA with family history of substance use started MA use earlier than others.

The comparison between different sequences of substance use and the number of family members who used substances showed that only sequencing F were statistically significant (P value = 0.03) (Table 5). The family history of substance use was found to be a risk factor for sequencing F (OR = 0.8).

The relationship between the use of stimulants in the family, including cocaine, MA, and Ritalin, showed no significant difference between sequences and use of stimulants in the family. No significant relationship was found between employment status and the age of onset of substance use as well as between different substance use and marital status.

**Discussion**

A number of studies have investigated the sequence of substance use initiation [20–23], suggesting that initiation of a substance and the sequence patterns of the substance use may be a risk factor for other behaviors. Fewer studies have investigated the sequence of substance use initiation for MA. The present study evaluated the sequential patterns of substance use before MA use disorders in Iran.

Our findings showed early onset of MA use in Iran. This early-onset MA use was significantly higher in those with lower income, primary education, no history of hospitalization, and family history of substance use. Tobacco followed by alcohol and opium, as starting substances, was found to be an important risk factor for MA use disorders. Sequencing D (tobacco-opium-MA) was the most common sequencing pattern in patients who used MA. Sequencing F (tobacco-alcohol-opium-heroin-MA) was significantly related to the early onset of MA use.

The abuse of substances, including MA, is associated with substantial costs and limited treatment options. Researches on the patterns and sequences of substance initiation provide a far more comprehensive portrait to develop suitable prevention and early intervention strategies.

In the present study, tobacco, followed by alcohol and opium, was found to be the first substance or starting substance used in patients with MA use, serving as a

| Table 2 | Relationship between different sequencing patterns and age of onset of substance use |
|---------|----------------------------------------------------------------------------------|
| Sequence | C (n = 19)* | D (n = 24)* | E (n = 17)* | F (n = 20)* | *P-value |
| Age started (mean ± SD) | 16.15 ± 4.34 | 17.04 ± 4.92 | 17 ± 3.77 | 12.05 ± 3.94 | < 0.0001 |

C (sequencing C: tobacco-opium-MA; D (sequencing D), tobacco-opium-heroin-MA; E (sequencing E: tobacco-alcohol-opium-heroin-MA; and F (sequencing F), tobacco-alcohol-opium-heroin-MA.
MA methamphetamine

Different values (superscripts a and b) of each row are significantly different.

*Values were analyzed by one-way analysis of variance (ANOVA); values are mean ± SD.
starting substance for initiation to MA use. Tobacco, alcohol and opium accounted for 93.71% of the first substances used by patients who used MA participated in this study. In a study carried out by Yen et al. in Taiwan, cigarette was found to be the most commonly used substance, and most adolescents had used cigarette, alcohol, areca quid, and glue before MA use [24]. No differences were found between cigarette smoking and alcohol use in their study with the present study; however, glue and areca quid are not used in Iran. In a study performed by Brecht et al. in California, tobacco, alcohol, and marijuana were found as a sequencing pattern for MA use in 95% cases [9]. The difference between marijuana and opium use seems to be due to the prevalence of opium use in Iran. Only 3 patients who used MA started with MA use (0.99%) in this study, which was consistent with the study conducted by Brecht et al. in California [9].

Prevalence of substance use in the last year was as follows:

1. The tobacco group, including hookah and cigarettes: 96% of the patients who used MA
2. The heroin group, including heroin and crack: 71.6% of the patients who used MA
3. The opium group, including opium and opium sap: 49.7% of the patients who used MA
4. The cannabis group, including marijuana and cannabis: 39.3% of the patients who used MA
5. The alcohol group, only including alcohol: 32.1% of the patients who used MA
6. The cocaine group, only including cocaine: 5.3% of the patients who used MA
7. The Ritalin group, only including Ritalin (methylphenidate): 1% of the patients who used MA

The prevalence of substance use in the past year was similar to that found in the study carried out by Darke et al. in Australia [10].

In this study, 46.1% of the people who used MA started before 15 years, while 53.9% of them started MA use after 15 years; the mean age of onset of the first substance use was 15.9 years. In the study carried out in Taiwan, 71% of the patients who used MA used substances after 15 years of age [24]; the reason for this difference can be attributed to the cohort effect, because the study of Yen et al. in Taiwan was carried out in 2005 while our study was performed in 2016, and the age of onset of substance use decreases over time. In a study conducted by Darke et al. in Australia [10], the mean age of the onset of substance use was 14 years, which was consistent with our findings.

Commonly-used sequencing patterns obtained in this study included D (tobacco-opium-heroin-MA; n = 24), F (tobacco-alcohol-cannabis-opium-heroin-MA; n = 20), C (tobacco-opium-MA; n = 19), E (tobacco-alcohol-opium-heroin-MA; n = 17), A (MA; n = 3), and B (tobacco-MA; n = 2), respectively. Common sequencing patterns obtained in the study carried out by Yen et al. in Taiwan [24] included MA as an initiator (n = 12), cigarette-MA (n = 86), cigarette-areca quid-MA (n = 41), cigarette-alcohol-MA (n = 39), alcohol-cocaine-MA (n = 12), cocaine-areca quid-alcohol-MA (n = 39), cigarette-areca quid-alcohol-MA (n = 39), and alcohol-areca quid-MA (n = 9). The difference between the sequence patterns can be attributed to the high prevalence of opioid use in Iran and the high prevalence of other substances such as Areca quid in Taiwan. However, the first 4 sequencing patterns showing high prevalence started with cigarettes both in the present study and in the study conducted in Taiwan [24].

Most patients who used MA participated in this study used heroin before MA (82%), but in the study carried out in Taiwan [24], none of the patients who used MA used heroin before MA, which could be due to the difference in the age of patients who used MA. In the study carried out in Taiwan [24], patients who used MA participated in that study were adolescents with 19 years or younger. In addition, previous studies showed that heroin is generally used in older adults [25]. Importantly, there are studies showing that the tendency to use different substances changes at different times and in different societies.

The comparison between the sequencing patterns of tobacco and cannabis use indicated that most patients

---

Table 3 Relationship between the age of onset of substance use and monthly income

| Monthly income | Low-income | Middle-income | High-income | Chi-square | Df | *P-value |
|----------------|------------|---------------|-------------|------------|----|----------|
| Early onset    | 76         | 44            | 19          | 10.146     | 2  | 0.006    |
| Late onset     | 67         | 81            | 15          |            |    |          |

* The chi-square test was used for the statistical differences

---

Table 4 The mean age of patients who used MA in starting groups

| First Substance     | Mean ± SD |
|---------------------|-----------|
| Opium               | 18.06 ± 7.41 |
| Methamphetamine     | 30 ± 14.93  |
| Cannabis            | 16.54 ± 4.03  |
| Heroin              | 19.83 ± 9.78  |
| Alcohol             | 15.79 ± 4.92  |
| Tobacco             | 15.25 ± 4.26  |
who used MA (93.29%) used tobacco earlier than cannabis, which was consistent with the study conducted by Darke et al. in Australia [10]. Inconsistent with these findings, the study conducted with Brecht et al. in California [9] showed that tobacco, marijuana, and alcohol acted as a sequential substance to MA use, in which alcohol was the most frequent substance to be used. This can be attributed to the frequency of alcohol availability and use as well as the increasing prevalence of marijuana use in recent years [26].

The comparison between the sequencing patterns and the age of onset of substance use showed that sequencing F (tobacco-alcohol-cannabis-opium-heroin-MA) was significantly related to early onset of substance use. This means that patients who used MA with lower age of onset used more substances before starting MA use. This finding was consistent with the studies carried out in Taiwan [24] and Australia [10], demonstrating that early onset of substance use has been associated with poly-drug abuse in the future.

In this study, there was a significant relationship between early onset of substance use and education; early onset of substance use was found in the patients who used MA with low educational levels while late onset of substance use was found in those with higher educational levels. In a study performed by Russell et al., a significant relationship was found between MA use and lower education, showing that patients who used MA generally had a lower education level [5]. The highest and lowest mean ages of onset of substance use were found to be 30 and 15.25 years in patients who used MA and tobacco, respectively; the mean ages of onset of opium, cannabis, alcohol, and heroin use were 18.68, 16.44, 15.59, and 19.83 years old, respectively. The mean ages of onset found in this study were lower as compared with the study conducted in California [9], in which patients who used alcohol had the lowest mean age, and patients who used heroin, followed by MA, had the highest mean age. The reason for the higher mean age of patients who used alcohol in our country and the present study can be attributed to religious beliefs about alcohol use.

In the present study, early onset of MA use was associated with a family history of substance use; in other words, patients who used MA with a family history of MA use started MA use earlier than other substances. In addition, sequencing F was also significantly associated with the greater number of family members with a history of substance use. In the studies carried out by Russell et al. [5] and Svingen et al. in Nebraska [27], a significant relationship was found between the family history of substance use and MA use in patients who used substances. The relationship between a family history of substance use and the age of onset of substance use showed that patients who used MA with a family history of substance use started to use substances 3.8 years earlier [28]; the results from these two studies were consistent with the results from this study.

The early age of onset of substance use was significantly associated with low monthly income. In most similar studies, the role of income levels was not investigated because those studies have chosen their samples from adolescents and only one study was presented descriptive income sources. In the study carried out by Darke et al. in Australia [10], 88, 21, and 7% of the patients who used MA derived their primary income from the government, criminal activity, and wages, respectively. In collection, the early age of substance use leads to less education, in turn resulting in lower-paid jobs.

To the best of our knowledge, this is the first study to examine the sequencing patterns of MA use, which can be the basis for future studies. However, the present study had some potential limitations, including the use of self-reporting, social desirability, selection bias and the low number of participants, especially female gender; the latter limitation led to no gender comparisons for variables. Therefore, the results may limit the generalizability of the results to some extent.

**Conclusions**

The present study is the first study to examine the sequential patterns of substance use for MA disorders in Iran. In this study, the early-onset MA use was

### Table 5 Relationship between drug sequences and family history of substance use

| Sequencing patterns | Family members with substance use | Family members with no substance use | chi-square | *P*-value | OR |
|---------------------|----------------------------------|--------------------------------------|------------|----------|-----|
| C                   | 13 (68.42)                       | 6 (31.58)                            | 0.92       | 0.24     | 1.14|
| D                   | 17 (70.83)                       | 7 (29.17)                            | 0.75       | 0.26     | 1.109|
| E                   | 14 (82.35)                       | 3 (17.65)                            | 0.22       | 0.45     | 0.94|
| F                   | 19 (95)                          | 1 (5)                                | 3.81       | 0.03     | 0.8 |

C (sequencing C): tobacco-opium-MA; D (sequencing D), tobacco-opium-heroin-MA; E (sequencing E): tobacco-alcohol-opium-heroin-MA; and F (sequencing F), tobacco-alcohol-cannabis-opium-heroin-MA.

MA methamphetamine

OR odds ratio

* The chi-square test was used for the statistical differences
significantly higher in patients who had lower income, primary education, no history of hospitalization, and family history of substance use. Tobacco, alcohol and opium were found to be as a sequential pattern for initiation to MA use.

Tobacco-alcohol-cannabis-opium-heroin-MA sequencing was significantly related to the early onset of the MA use.

Findings from this study may support targeted prevention efforts and development of more effective interventions. Standardized measures to decrease and control access to main starting and sequencing substances, including tobacco, alcohol, and opium, can not only greatly help decrease the early onset of the MA use, but also lead to development of suitable prevention and early intervention strategies. In addition, programs focusing on increasing knowledge and changing the attitudes of adolescents toward drug abuse can assist to prevent MA use through decreased use of these substances in the society. However, because of gender limitations, it is recommended to include more women users in future studies in order to make gender comparisons possible.

Abbreviation
MA: Methamphetamine

Acknowledgements
The authors would like to announce their appreciation to all patients participated in this study. We also wish to thank Dr. Somaye Youseae and Mr. Mohammadreza Rajabalipour for their help in statistical analysis.

Declarations
This study was carried out in accordance with the recommendations of ethical guidelines, IR.SUMS.REC.1394.S1206. The research protocol was approved by Shiraz University of Medical Sciences. All subjects were given written informed consent in accordance with the Declaration of Helsinki.

Authors’ contributions
EMS, M A-A, and MM-B conceptualized the study. BO, AB, ERY, and MDM contributed to data collection. MM-B executed the analysis. JA and MK wrote Funding
This research was supported by Shiraz University of Medical Sciences (IR.SUMS.REC.1394.S1206).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the Shiraz University of Medical Sciences on reasonable request.

Ethics approval and consent to participate
The current study was conducted in accordance with the recommendations of ethical guidelines, IR.SUMS.REC.1394.S1206. The research protocol was approved by Shiraz University of Medical Sciences. All subjects were given written informed consent in accordance with the Declaration of Helsinki. The data used in this study are public and as such this study is exempt from human subject’s review.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Research Center for Psychiatry and Behavior Science, Shiraz university of Medical Sciences, Shiraz, Iran. 2Substance Abuse Research Center, Dual Diagnosis Ward, Shiraz University of Medical Sciences, Shiraz, Iran.
3Department of Psychiatry, Psychosomatic Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. 4Infectious Disease Research Center, Birjand University of Medical Sciences, Birjand, Iran. 5Department of Clinical Pharmacy, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran. 6Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. 7Department of Humanistic Sciences, Islamic Azad University of Yazd, Yazd, Iran. 8Department of Clinical Microbiology, Iranshahr University of Medical Sciences, Iranshahr, Iran. 9Department of Midwifery, School of Nursing and Midwifery, Iranshahr University of Medical Sciences, Iranshahr, Iran. 10NanoBioelectrochemistry Research Center, Barn University of Medical Sciences, Barn, Iran. 11Cellular and Molecular Biology Research Center, Larestan University of Medical Sciences, Larestan 743189335, Iran.

Received: 18 September 2019 Accepted: 22 July 2020
Published online: 29 July 2020

References
1. Favrod-Coune T, Broers B. The health effect of Psychostimulants: A literature review. Pharmaceuticals (Basel). 2010;3(7):233–61.
2. Juarez-Portilla C, Kim RD, Robotham M, Tariq M, Pitter M, LeSauter J, Lihrer R. Voluntary inhalation of methamphetamine: a novel strategy for studying intake non-invasively. Psychopharmacology. 2017;234(5):739–47.
3. Paneriak WJ, Procsyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WGBatt A M. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013;129(3):167–79.
4. Albertson TE, Chenoweth JA, Colby D, Sutter M E. The Changing Drug Culture: Medical and Recreational Marijuana. PF Essent. 2016;411(11–7).
5. Russell K, Dryden DM, Liang Y, Friesen C, O’Gorman K, Duret T, Wild TC, et al. Risk factors for methamphetamine use in youth: a systematic review. BMC Pediatr. 2009;8:48.
6. Chiang M, Lombardi D, Du J, Makrum U, Sithichai R, Harrington A, Shukair N, et al. Methamphetamine-associated psychosis: clinical presentation, biological basis, and treatment options. Hum Psychopharmacol. 2019;34(5):e2710.
7. Chomchai C, Chomchai S. Global patterns of methamphetamine use. Curr Opin Psychiatry. 2015;28(4):269–74.
8. Wang G, Zhang Y, Zhang S, Chen H, Xu Z, Schottenfeld RS, Hao W, et al. Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients. J Subst Abus Treat. 2016;62:848–8.
9. Brecht ML, Greenwell L, Aingin MD. Substance use pathways to methamphetamine use among treated users. Addict Behav. 2007;32(1):224–38.
10. Darke S, Kaye ST, Ork M. Age-related patterns of drug use initiation among polydrug using regular psychostimulant users. Drug and alcohol review. 2012;31(1):236–9.
11. Rajabalipour M, Khoshab H, Banihash M, Nahakae N, Sharifi H, Tavakoli Firanpour A. Using social cognitive theory to investigate the risk factors of Waterpipe smoking among southeastern Iranian adolescents. Int J Pediatr. 2019;7(10):10243–53.
12. Jalali A, Behrouzi MK, Salari N, Bazrafshan MRahmati M. The effectiveness of group spiritual intervention on self-esteem and happiness among men undergoing methadone maintenance treatment. Curr Drug Res Rev. 2019;11(1):67–72.
13. Noroozi M, Armouon B, Ghisvand H, Noroozi A, Karimy M, Bazrafshan MR, Marshall BDL, et al. Prevalence and risk factors for injection site skin infections among people who inject drugs (PWID) in Tehran. J Cosmet Dermatol. 2019;18(1):259–62.
14. Montazi S, Rawson R. Substance abuse among Iranian high school students. Curr Opin Psychiatry. 2010;23(3):221–6.
15. Alam-Mehrjerdi Z, Mokri AD, Kolan M. Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country. Asian J Psychiatr. 2015;16:17–25.
16. Hamdieh M, Borujerdi A, Motalebi N, Abbasinejad M, Asheri HM, Motamedi A. The prevalence of cigarette smoking, alcohol consumption, Psychostimulant and cannabinoid drugs abuse among 15 to 35 years old Tehranis. Iran J Psychiatry Behav Sci. 2010;4(2):26–30.

17. Narenjiha H, Rafiey H, Jahani MR, Assari S, Moharamzad Y, Roshanpazooh M. Substance-dependent professional drivers in Iran: a descriptive study. Traffic Inj Prev. 2009;10(3):227–30.

18. Angoorani H, Narenjiha H, Tayebei B, Ghassabian A, Ahmadi G, Assari S. Amphetamine use and its associated factors in body builders: a study from Tehran. Iran Arch Med Sci. 2012;8(2):362–7.

19. White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, Kendall C, et al. Strengthening the reporting of observational studies in epidemiology for respondent-driven sampling studies: "STROBE-RDS" statement. J Clin Epidemiol. 2015;68(12):1463–71.

20. Yimsaard P, Maes MM, Verachai V, Kalayasiri R. Pattern of methamphetamine use and the time lag to methamphetamine dependence. J Addict Med. 2018;12(2):92–8.

21. Guerra LM, Romano PS, Samuels S, Kass P H. Ethnic differences in adolescent substance initiation sequences. Arch Pediatr Adolesc Med. 2000; 154(11):1089–95.

22. Navaratnam V, Foong K. Sequence of onset of different drug use among opiate addicts. Curr Med Res Opin. 1989;11(9):600–9.

23. Sartor CE, Kranzler HR, Gelernter J. Characteristics and course of dependence in cocaine-dependent individuals who never used alcohol or marijuana or used cocaine first. J Stud Alcohol Drugs. 2014;75(3):423–7.

24. YEN C, YANG Y, KO CY, YEN J. Substance initiation sequences among Taiwanese adolescents using methamphetamine. Psychiatry Clin Neurosci. 2005;59(6):683–9.

25. Reid LW, Ellifson K, WsSterk CE. Ecstasy and gateway drugs: initiating the use of ecstasy and other drugs. Ann Epidemiol. 2007;17(1):74–80.

26. Schratzadeh M, Niazi M, Menati R, Karsani AM, Menati W. The prevalence of methamphetamine use among Iranian male students: a systematic review and meta-analysis. J Sabzevar Univ Med Sci. 2016;22(7):1170–9.

27. Svingen L, Dykstra RE, Simpson JL, Jaffe AE, Bevins RA, Catfo G, DiLillo D, et al. Associations between family history of substance use, childhood trauma, and age of first drug use in persons with methamphetamine dependence. J Addict Med. 2016;10(4):269–73.

28. Sharifi H, Sadr M, Abdolahinia MA, Sajjadi M. Study of the relationship between tobacco use and drug use: is tobacco smoking a gateway to drug use? Nafas. 2013;2(1):19–24.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.